Recent trials on the newer GLP-1 agents including tirzepatide and semaglutide specific to weight loss have not demonstrated increased rates of pancreatitis, although product labeling still instructs avoidance in patients with a history of pancreatitis [167,168,169]. The gene discussed is GLP1R; the disease is pancreatitis.